These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19455306)

  • 1. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.
    Suarez-Pinzon WL; Cembrowski GS; Rabinovitch A
    Diabetologia; 2009 Aug; 52(8):1680-2. PubMed ID: 19455306
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
    Tian L; Gao J; Hao J; Zhang Y; Yi H; O'Brien TD; Sorenson R; Luo J; Guo Z
    Endocrinology; 2010 Jul; 151(7):3049-60. PubMed ID: 20444936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
    Cabrera SM; Colvin SC; Tersey SA; Maier B; Nadler JL; Mirmira RG
    Clin Exp Immunol; 2013 Jun; 172(3):375-82. PubMed ID: 23600825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice.
    da Silva Faria AL; Dias MA; Leme VB; Mayoral EE; da Silva RE; Mâncio RD; Ferreira Junior RS; Caldeira EJ
    Arch Oral Biol; 2013 Jul; 58(7):755-61. PubMed ID: 23107049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.
    Xue S; Posgai A; Wasserfall C; Myhr C; Campbell-Thompson M; Mathews CE; Brusko T; Rabinovitch A; Savinov A; Battaglia M; Schatz D; Haller M; Atkinson MA
    Diabetes; 2015 Nov; 64(11):3873-84. PubMed ID: 26185279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
    Tanimura Y; Aoi W; Mizushima K; Higashimura Y; Naito Y
    Exp Physiol; 2019 Jul; 104(7):1051-1060. PubMed ID: 31020720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration.
    Weir GC; Bonner-Weir S
    Endocrinology; 2010 Jul; 151(7):2971-3. PubMed ID: 20570953
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
    J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-immune-based treatment for type 1 diabetes: the way to go?
    Rigby MR
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):681-2. PubMed ID: 24997558
    [No Abstract]   [Full Text] [Related]  

  • 13. A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Zhu MR; Zhou J; Jin Y; Gao LH; Li L; Yang JR; Lu CM; Zhao QH; Xie MJ
    Int J Biol Macromol; 2018 Dec; 120(Pt A):1232-1239. PubMed ID: 30171949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2009 Mar; 58(3):641-51. PubMed ID: 19073764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
    Bhattacharjee A; Allister EM; Wheeler MB
    Can J Physiol Pharmacol; 2012 May; 90(5):663-8. PubMed ID: 22530993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition.
    Zhong J; Goud A; Rajagopalan S
    Circ Heart Fail; 2015 Jul; 8(4):819-25. PubMed ID: 26199308
    [No Abstract]   [Full Text] [Related]  

  • 19. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.